For qualified non-clinical research buyers, including independent researchers, educators, analysts and research teams. Not for human or veterinary use.

Research evidence guide

Tesamorelin research starts with identity, matrix and method.

A cited buyer guide to the modified GHRH analog, plasma-degradation evidence, non-clinical models, immunoaffinity LC-MS methods and current eligible research formats.

Evidence snapshotTesamorelin, also reported as TH9507, is a modified human growth-hormone-releasing-factor analog. Identity, degradation and detection findings depend on the exact analyte, matrix and analytical workflow.[1][2]

Compare current prices and formats.

For qualified non-clinical research buyers. Not for human or veterinary use.

Disclosure: We may earn a commission from purchases made through our links.

Define the exact analog first

PubChem represents tesamorelin as CID 16137828 with molecular formula C221H366N72O67S and molecular weight 5136.[1] A non-clinical paper describes TH9507 as human growth-hormone-releasing factor 1–44 amide modified with a trans-3-hexenoyl group at Tyr1.[2] These records help define the literature analyte, but neither authenticates a seller lot or establishes its salt, counterion, quantity basis, purity, stability or experimental performance.

Chemical database evidencePubChem supplies a structure-level tesamorelin record; it is not batch-specific documentation.[1]
Non-clinical identity and degradation evidenceThe TH9507 study compared degradation in rat, dog and human plasma and reported animal pharmacology and toxicology observations.[2]

Modification and matrix belong with every stability result

The non-clinical study reported slower in-vitro plasma degradation for TH9507 than for unmodified hGRF(1–44)NH2 and described animal exposure and biomarker measurements.[2] Species, plasma preparation, temperature, sampling interval, immunoreactivity method and comparator identity are part of that result. It should not be converted into a universal shelf-life, storage or performance claim.

Evidence boundary: chemical-database identity, plasma degradation, animal pharmacology, immunoaffinity recovery and mass-spectrometric detection answer different questions. None verifies the identity, purity, stability or performance of a current seller lot.

Analytical detection requires a defined workflow

A validated plasma method used immunoaffinity purification followed by nano-UHPLC high-resolution tandem mass spectrometry to detect several growth-hormone-releasing hormones, including tesamorelin.[3] Reported recovery, detection limits and matrix effects belong to that method and specimen type; they are not product specifications.

A broader peptide method combined ultrafiltration, immunoaffinity purification, nano-UHPLC and high-resolution tandem mass spectrometry for analytes above 2 kDa.[4] Its recovery and sensitivity varied across analytes and matrices, showing why one platform label such as “LC-MS” is not enough to compare methods.

Parent peptide and metabolites are separate targets

A 2021 analytical study investigated tesamorelin and other GHRH analogs in fortified urine, identified in-vitro metabolites and developed an LC–tandem-MS method using characterized reference materials.[5] A later nano-LC quadrupole/Orbitrap study evaluated extraction, cleanup, selectivity, reliability, carryover, identification limits, robustness, autosampler stability and matrix effects for GHRH-related targets in urine.[6] These are analytical-method records in anti-doping matrices—not claims about suitability or results for a seller product.

Procurement and method checks for tesamorelin

  • Confirm the requested material name, 44-residue analog identity, Tyr1 modification, terminal state, salt or counterion and quantity basis when supplied.
  • Match current documentation to the exact listing and received lot; database and literature records are not lot evidence.
  • Define whether the analytical target is intact parent peptide, a specified metabolite, an impurity or a degradation product.
  • Record specimen or buffer matrix, extraction, cleanup, recovery, internal standard, chromatographic separation, precursor/product ions and acceptance criteria.
  • Keep immunoreactivity, high-resolution mass detection and biological-response measurements as separate evidence classes.
  • Verify current seller price, availability, shipment eligibility and institutional receiving requirements before ordering.

Review current research formats

The cards below use current seller-catalog title, format, price and availability facts retrieved during generation. The literature above does not establish the identity, quality, purity, stability, performance or results of the seller product.

Sources

  1. PubChem Compound Summary: Tesamorelin, CID 16137828 — chemical database record.
  2. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue — plasma-degradation and rat, dog and pig non-clinical study.
  3. Qualitative identification of growth hormone-releasing hormones in human plasma by immunoaffinity purification and LC-HRMS/MS — analytical-method study.
  4. Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS — multi-analyte method-validation study.
  5. Advances in the detection of growth hormone releasing hormone synthetic analogs — fortified-urine metabolism and LC-MS/MS method study.
  6. Analysis of growth hormone releasing hormone and its analogs in urine using nano-LC quadrupole/Orbitrap mass spectrometry — urine sample-preparation and method-validation study.